Today's market saw significant capital activity, with Triple Point Venture VCT successfully raising £9.3 million through an equity issuance and EQTEC PLC completing a corporate reset that included a £1.3 million fundraise and debt restructuring, alongside a strategic expansion into critical metals. Institutional and insider confidence were also notable, as BlackRock increased its holding in AIB Group to 10.98% and Raspberry Pi Holdings' CEO acquired additional shares. Strategic operational advancements included Crystal Amber Fund’s portfolio company Morphic Medical securing European and UK regulatory approvals for its obesity device, while Feedback PLC bolstered its board with the appointment of Emma Oswick as Chief Financial Officer.
Energy transition company EQTEC EQT announced the completion of its comprehensive corporate reset, which involved a successful equity fundraise of £1.3 million and a significant restructuring of its existing debt facilities. Additionally, the acquisition of a copper-gold exploration asset, along with an option over a second project, is expected to finalize shortly. This strategic shift complements its core gasification technology, diversifying its portfolio into critical and precious metals, and aims to unlock new value catalysts for the company.
Raspberry Pi Holdings RPI announced that its Chief Executive Officer, Eben Upton, has purchased ordinary shares in the company. Following this transaction, his total shareholding now stands at 2,591,136 shares. A significant purchase by a key executive like the CEO is often interpreted as a strong signal of insider confidence in the company's valuation and future strategic direction, providing a positive indicator for investors.
Investment vehicle Crystal Amber Fund CRS updated the market on Morphic Medical, Inc., a key holding that developed Reset®, a medical device targeting obesity and type 2 diabetes. Morphic Medical has successfully secured the European CE mark and UK regulatory approval for its system, leading to initial patient procedures in the UK and India. Furthermore, the company has signed distribution agreements across Europe and the Middle East, with accelerated patient recruitment for its crucial US FDA study, projected to complete between late 2027 and early 2028.
Clinical infrastructure specialist Feedback FDBK confirmed the appointment of Emma Oswick as its Chief Financial Officer to the company's Board of Directors, effective today. Ms. Oswick joined Feedback in November 2025, bringing significant experience in subscription-led technology businesses, having previously served as Interim CFO at Energy Aspects. Her expertise in driving strategic change, optimizing financial performance, and M&A integration is expected to be instrumental in positioning Feedback for future growth.
Irish banking group AIB Group AIBG announced a major holding notification from BlackRock, Inc. The global asset manager increased its total position in AIB Group to 10.98% of voting rights, up from 10.00% previously. This new threshold was crossed on February 13, 2026. Such a significant stake held by a prominent institutional investor like BlackRock can be seen as a strong indicator of confidence in AIB Group's performance and future prospects, signaling increased institutional interest in the company.
Venture Capital Trust Triple Point Venture VCT TPV announced the allotment of 9,866,963 Venture Shares. These shares were issued at an average price of 94.638 pence per share, successfully raising approximately £9.3 million through an offer for subscription detailed in a September 2025 prospectus. The new shares are expected to be admitted to the Official List around February 17, 2026, bringing the company's total issued share capital and voting rights to 119,889,748 Venture Class Shares. This fundraising strengthens its capacity for future investments.